Rino Rappuoli

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. pmc The key role of genomics in modern vaccine and drug design for emerging infectious diseases
    Kate L Seib
    Novartis Vaccines and Diagnostics, Siena, Italy
    PLoS Genet 5:e1000612. 2009
  2. pmc The challenge of developing universal vaccines
    Rino Rappuoli
    Novartis Vaccines and Diagnostics Via Fiorentina 1, 53100 Siena Italy
    F1000 Med Rep 3:16. 2011
  3. doi request reprint Vaccine adjuvants: the future is bright
    Rino Rappuoli
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Expert Rev Vaccines 12:727-9. 2013
  4. doi request reprint Influenza: options to improve pandemic preparation
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, Siena, Italy
    Science 336:1531-3. 2012
  5. ncbi request reprint The design of semi-synthetic and synthetic glycoconjugate vaccines
    Paolo Costantino
    Novartis Vaccines, Via Fiorentina 1, Siena 53100, Italy
    Expert Opin Drug Discov 6:1045-66. 2011
  6. ncbi request reprint ADITEC: joining forces for next-generation vaccines
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Sci Transl Med 4:128cm4. 2012
  7. doi request reprint Vaccines for the twenty-first century society
    Rino Rappuoli
    Novartis Vaccines and Diagnostics Srl, Via Fiorentina 5, 53100 Siena, Italy
    Nat Rev Immunol 11:865-72. 2011
  8. pmc Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species
    Claudio Donati
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Genome Biol 11:R107. 2010
  9. pmc Twenty-first century vaccines
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Philos Trans R Soc Lond B Biol Sci 366:2756-8. 2011
  10. doi request reprint A 2020 vision for vaccines against HIV, tuberculosis and malaria
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Nature 473:463-9. 2011

Detail Information

Publications145 found, 100 shown here

  1. pmc The key role of genomics in modern vaccine and drug design for emerging infectious diseases
    Kate L Seib
    Novartis Vaccines and Diagnostics, Siena, Italy
    PLoS Genet 5:e1000612. 2009
    ..This ever-growing body of genomic data and new genome-based approaches will play a critical role in the future to enable timely development of vaccines and therapeutics to control emerging infectious diseases...
  2. pmc The challenge of developing universal vaccines
    Rino Rappuoli
    Novartis Vaccines and Diagnostics Via Fiorentina 1, 53100 Siena Italy
    F1000 Med Rep 3:16. 2011
    ..This review describes the progress made towards the development of vaccines inducing broad protection against Neisseria meningitidis, influenza, HIV, and Candida and the challenges of developing truly universal vaccines...
  3. doi request reprint Vaccine adjuvants: the future is bright
    Rino Rappuoli
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Expert Rev Vaccines 12:727-9. 2013
    Interview by Jenaid Rees, Commissioning Editor Rino Rappuoli is the Global Head of Vaccines Research at Novartis Vaccines & Diagnostics (Siena, Italy)...
  4. doi request reprint Influenza: options to improve pandemic preparation
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, Siena, Italy
    Science 336:1531-3. 2012
    ..Here, we review the options available in the short term and also briefly address the solutions that research may make available in the long term...
  5. ncbi request reprint The design of semi-synthetic and synthetic glycoconjugate vaccines
    Paolo Costantino
    Novartis Vaccines, Via Fiorentina 1, Siena 53100, Italy
    Expert Opin Drug Discov 6:1045-66. 2011
    ..New and challenging targets for conjugate vaccines are represented by cancer and other non-infectious diseases...
  6. ncbi request reprint ADITEC: joining forces for next-generation vaccines
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Sci Transl Med 4:128cm4. 2012
    ..The European Commission-sponsored Advanced Immunization Technologies project--ADITEC--brings together some of the leading laboratories in the field to tackle the problems that no lab can tackle in isolation...
  7. doi request reprint Vaccines for the twenty-first century society
    Rino Rappuoli
    Novartis Vaccines and Diagnostics Srl, Via Fiorentina 5, 53100 Siena, Italy
    Nat Rev Immunol 11:865-72. 2011
    ..Supported by the innovations derived from new technologies, vaccines will address the new needs of a twenty-first century society characterized by increased life expectancy, emerging infections and poverty in low-income countries...
  8. pmc Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species
    Claudio Donati
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Genome Biol 11:R107. 2010
    ..Streptococcus pneumoniae is one of the most important causes of microbial diseases in humans. The genomes of 44 diverse strains of S. pneumoniae were analyzed and compared with strains of non-pathogenic streptococci of the Mitis group...
  9. pmc Twenty-first century vaccines
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Philos Trans R Soc Lond B Biol Sci 366:2756-8. 2011
    ..However, for this to happen, we need to increase the public trust in vaccination so that vaccines can be perceived as the best insurance against most diseases across all ages...
  10. doi request reprint A 2020 vision for vaccines against HIV, tuberculosis and malaria
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Nature 473:463-9. 2011
    ..We also argue that new and innovative approaches to clinical trials will accelerate the availability of these vaccines...
  11. doi request reprint Vaccine discovery and translation of new vaccine technology
    Rino Rappuoli
    Novartis Vaccines, Siena, Italy
    Lancet 378:360-8. 2011
    ....
  12. ncbi request reprint Building an insurance against modern pandemics
    Rino Rappuoli
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Curr Opin Investig Drugs 11:126-30. 2010
    ..The lessons learned from the 2009 H1N1 pandemic are of paramount importance to develop more effective preparations against future pandemics...
  13. ncbi request reprint Bridging the knowledge gaps in vaccine design
    Rino Rappuoli
    Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Nat Biotechnol 25:1361-6. 2007
  14. ncbi request reprint Identification of a new OmpA-like protein in Neisseria gonorrhoeae involved in the binding to human epithelial cells and in vivo colonization
    Laura Serino
    Research Centre, Novartis Vaccines, Via Fiorentina, 1, 53100 Siena, Italy
    Mol Microbiol 64:1391-403. 2007
    ..All together, these data suggest that the newly identified surface exposed protein Ng-OmpA represents a novel virulence factor of gonococcus...
  15. pmc Identification of a universal Group B streptococcus vaccine by multiple genome screen
    Domenico Maione
    Chiron Srl, Via Fiorentina 1, 53100 Siena, Italy
    Science 309:148-50. 2005
    ..Multigenome analysis and screening described here represent a powerful strategy for identifying potential vaccine candidates against highly variable pathogens...
  16. pmc Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein
    Karin Baraldo
    Research Center, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Infect Immun 73:5835-41. 2005
    ..Taken together, these data show that the N19 polyepitope represents a strong and valid option for the generation of improved or new combined glycoconjugate vaccines...
  17. doi request reprint Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis
    Maria Scarselli
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    J Mol Biol 386:97-108. 2009
    ....
  18. pmc Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
    Grazia Galli
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy
    Proc Natl Acad Sci U S A 106:3877-82. 2009
    ..We suggest that CD4(+) T cell priming might be used as an early predictor of the immunogenicity of prepandemic vaccines...
  19. pmc A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells
    Fabio Bagnoli
    Department of Cellular Microbiology and Bioinformatics, Novartis Vaccines, University of Siena, Siena 53100, Italy
    J Bacteriol 190:5480-92. 2008
    ..Thus, pneumococci encode at least two types of pili that play a role in the initial host cell contact to the respiratory tract and are potential antigens for inclusion in a new generation of pneumococcal vaccines...
  20. pmc Neisseria meningitidis NalP cleaves human complement C3, facilitating degradation of C3b and survival in human serum
    Elena Del Tordello
    Research Center, Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 111:427-32. 2014
    ..We conclude that NalP is an important factor to increase the survival of Nm in human serum. ..
  21. pmc A universal vaccine for serogroup B meningococcus
    Marzia M Giuliani
    Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 103:10834-9. 2006
    ..The strain coverage could be increased to 90% and above by the addition of CpG oligonucleotides or by using MF59 as adjuvant. The vaccine has the potential to conquer one of the most devastating diseases of childhood...
  22. pmc Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen
    Enrico Malito
    Research Center, Novartis Vaccines and Diagnostics Srl, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 110:3304-9. 2013
    ....
  23. ncbi request reprint Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system
    Barbara C Baudner
    Research Center, Chiron Srl, Siena, Italy
    J Infect Dis 189:828-32. 2004
    ..These data could affect the design of efficacious mucosal vaccines and their safety...
  24. ncbi request reprint The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature
    Elaine Tritto
    Novartis Vaccines and Diagnostics, Siena, Italy
    J Immunol 179:5346-57. 2007
    ..Our data suggest that LTK63 acts as an airway infection mimic that establishes a generic protective environment limiting respiratory infection by innate immune mechanisms and by improving adaptive responses to invading pathogens...
  25. pmc Sortase A confers protection against Streptococcus pneumoniae in mice
    Claudia Gianfaldoni
    Novartis Vaccines and Diagnostics Srl, Research Center, Siena, Italy
    Infect Immun 77:2957-61. 2009
    ..Taken together, our results suggest that SrtA is a good candidate for inclusion in a multicomponent, protein-based, pneumococcal vaccine...
  26. pmc Pilus operon evolution in Streptococcus pneumoniae is driven by positive selection and recombination
    Alessandro Muzzi
    Novartis Vaccines and Diagnostics, Siena, Italy
    PLoS ONE 3:e3660. 2008
    ....
  27. ncbi request reprint Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin
    Maria Scarselli
    Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Mol Microbiol 61:631-44. 2006
    ..Collectively, our results underline a putative role of NhhA in meningococcal pathogenesis and ascertain its structural and functional belonging to the emerging group of bacterial autotransporter adhesins with trimeric architecture...
  28. ncbi request reprint NarE: a novel ADP-ribosyltransferase from Neisseria meningitidis
    Vega Masignani
    IRIS, Chiron s r l, Via Fiorentina 1, 53100 Siena, Italy
    Mol Microbiol 50:1055-67. 2003
    ..When present, the gene is 100% conserved in sequence and is inserted upstream of and co-transcribed with the lipoamide dehydrogenase E3 gene. Possible roles in the pathogenesis of N. meningitidis are discussed...
  29. doi request reprint Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection
    Kate L Seib
    Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 28:2416-27. 2010
    ....
  30. doi request reprint Rational design of a meningococcal antigen inducing broad protective immunity
    Maria Scarselli
    Novartis Vaccines and Diagnostics s r l, Via Fiorentina 1, 53100 Siena, Italy
    Sci Transl Med 3:91ra62. 2011
    ..We demonstrate that the structure-based design of multiple immunodominant antigenic surfaces on a single protein scaffold is possible and represents an effective way to create broadly protective vaccines...
  31. pmc Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans
    Davide Serruto
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 107:3770-5. 2010
    ..We conclude that GNA2132 is an important protective antigen of N. meningitidis and we propose to rename it, Neisserial Heparin Binding Antigen (NHBA)...
  32. pmc Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A
    Markus Hilleringmann
    Research Center, Novartis Vaccines and Diagnostics s r l, Siena, Italy
    PLoS Pathog 4:e1000026. 2008
    ..Combining the structural and functional data, a model emerges where the pilus RrgB backbone serves as a carrier for surface located adhesive clusters of RrgA that facilitates the interaction with the host...
  33. doi request reprint HadA is an atypical new multifunctional trimeric coiled-coil adhesin of Haemophilus influenzae biogroup aegyptius, which promotes entry into host cells
    Davide Serruto
    Research Center, Novartis Vaccines and Diagnostics, Siena, Italy
    Cell Microbiol 11:1044-63. 2009
    ..These data give new insights on the structure-function relationship of oligomeric coiled-coil adhesins and suggest a potential role of this protein in the pathogenesis of BPF...
  34. doi request reprint Genome-based vaccine development: a short cut for the future
    Danilo Gomes Moriel
    Novartis Vaccines, Via Fiorentina 1, 53100, Siena, Italy
    Adv Exp Med Biol 655:81-9. 2009
    ..A lot of work must be done, but deciphering the information provided by genome sequences and using it to better understand the host-pathogen interactions has proved to be the key for protection...
  35. pmc Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination
    Sonia Budroni
    Research Center, Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 108:4494-9. 2011
    ....
  36. ncbi request reprint Neisseria gonorrhoeae PIII has a role on NG1873 outer membrane localization and is involved in bacterial adhesion to human cervical and urethral epithelial cells
    Rosanna Leuzzi
    Novartis Vaccines and Diagnostics, S, R, L, Via Fiorentina 1, Siena 53100, Italy
    BMC Microbiol 13:251. 2013
    ..The contribution of PIII in the membrane architecture and its role in the interaction with epithelial cells has never been investigated...
  37. pmc RrgB321, a fusion protein of the three variants of the pneumococcal pilus backbone RrgB, is protective in vivo and elicits opsonic antibodies
    Carole Harfouche
    Research Center, Novartis Vaccines and Diagnostics s r l, Siena, Italy
    Infect Immun 80:451-60. 2012
    ..These results suggest that a vaccine composed of RrgB321 has the potential to cover 30% or more of all pneumococcal strains and support the inclusion of this fusion protein in a multicomponent vaccine against S. pneumoniae...
  38. pmc Streptococcus pneumoniae pilus subunits protect mice against lethal challenge
    Claudia Gianfaldoni
    Novartis Vaccines and Diagnostics s r l, Research Center, Via Fiorentina 1, I 53100 Siena, Italy
    Infect Immun 75:1059-62. 2007
    ..Both active and passive immunization with recombinant pilus subunits afforded protection against lethal challenge with the S. pneumoniae serotype 4 strain TIGR4...
  39. doi request reprint Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related
    Monica Moschioni
    Novartis Vaccines, Siena, Italy
    J Infect Dis 197:888-96. 2008
    ..Limited data are available on the prevalence of the rlrA operon in pneumococci; therefore, we investigated its distribution and its antigenic variation among disease-causing strains...
  40. ncbi request reprint Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus
    Marzia M Giuliani
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy
    Vaccine 28:5023-30. 2010
    ....
  41. doi request reprint Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1
    Brunella Brunelli
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 29:1072-81. 2011
    ....
  42. pmc Vaccinology in the genome era
    C Daniela Rinaudo
    Novartis Vaccines, Siena, Italy
    J Clin Invest 119:2515-25. 2009
    ..Furthermore, structural vaccinology is emerging as a powerful tool for the rational design or modification of vaccine antigens to improve their immunogenicity and safety...
  43. ncbi request reprint Structural insight into the mechanism of DNA-binding attenuation of the Neisserial adhesin repressor NadR by the small natural ligand 4-hydroxyphenylacetic acid
    Sébastien Brier
    Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100, Siena, Italy
    Biochemistry 51:6738-52. 2012
    ..Altogether our data suggest that the mechanism of regulation of NadR by 4-HPA mainly involves the stabilization of the dimer in a configuration incompatible with DNA binding...
  44. ncbi request reprint Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice
    Andreas Wack
    Novartis Vaccines, Via Fiorentina 1, Siena, Italy
    Vaccine 26:552-61. 2008
    ..These observations have significant implications for the development of new and improved flu vaccines against pandemic and inter-pandemic influenza virus strains...
  45. doi request reprint Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus
    Stefania Bambini
    Novartis V and D, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 27:2794-803. 2009
    ..Sequencing each gene in the different strains will be important to evaluate antigen conservation and assortment and to allow a future prediction of potential vaccine coverage...
  46. ncbi request reprint Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells
    Barbara Capecchi
    Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Mol Microbiol 55:687-98. 2005
    ..NadA is likely to improve the fitness of N. meningitidis contributing to the increased virulence of strains that belong to the hypervirulent lineages...
  47. pmc Molecular architecture of Streptococcus pneumoniae TIGR4 pili
    Markus Hilleringmann
    Research Center, Novartis Vaccines and Diagnostics s r l, Siena, Italy
    EMBO J 28:3921-30. 2009
    ..Our structural analyses provide the first direct experimental evidence that the native S. pneumoniae pilus shaft is composed exclusively of covalently linked monomeric RrgB subunits oriented head-to-tail...
  48. ncbi request reprint Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach
    Marirosa Mora
    Novartis Vaccines, Via Fiorentina, 53100 Siena, Italy
    Curr Opin Microbiol 9:532-6. 2006
    ..The practical consequence is that, in many cases, a universal vaccine is possible only by including a combination of antigens and this combination must take into account the pathogen population structure...
  49. pmc Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies
    Kate L Seib
    Molecular Genetics Unit, Novartis Vaccines, Via Fiorentina, 1, 53100 Siena, Italy
    Infect Immun 79:970-81. 2011
    ..Furthermore, cross-reactive bactericidal activity was seen within each variant group, although the degree of activity varied, suggesting that amino acid differences within each variant group influence the bactericidal antibody response...
  50. pmc In vitro analysis of protein-operator interactions of the NikR and fur metal-responsive regulators of coregulated genes in Helicobacter pylori
    Isabel Delany
    Molecular Immunology Unit, Chiron Vaccines, Siena, Italy
    J Bacteriol 187:7703-15. 2005
    ..Finally, the importance of an interconnection between metal-responsive gene networks for homeostasis is discussed...
  51. pmc Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines
    John Donnelly
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 107:19490-5. 2010
    ..This assay allows typing of large panels of strains and prediction of coverage of protein-based meningococcal vaccines. Similar assays may be used for protein-based vaccines against other bacteria...
  52. ncbi request reprint Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens
    Davide Serruto
    IRIS, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    J Biotechnol 113:15-32. 2004
    ..In addition, we describe the potential of these powerful technologies in understanding the pathogenesis of various bacteria...
  53. pmc Vaccines, reverse vaccinology, and bacterial pathogenesis
    Isabel Delany
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Cold Spring Harb Perspect Med 3:a012476. 2013
    ....
  54. doi request reprint The factor H binding protein of Neisseria meningitidis interacts with xenosiderophores in vitro
    Daniele Veggi
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena, Italy
    Biochemistry 51:9384-93. 2012
    ..Our results indicated that the enterobactin binding site was distinct from the site involved in binding to human factor H and stimulates new hypotheses about possible multiple activities of fHbp...
  55. pmc Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival
    Hebert Echenique-Rivera
    Novartis Vaccines and Diagnostics, Siena, Italy
    PLoS Pathog 7:e1002027. 2011
    ..This increased knowledge of how Nm responds to adaptation in blood could also be helpful to develop diagnostic and therapeutic strategies to control the devastating disease cause by this microorganism...
  56. doi request reprint Designing the next generation of vaccines for global public health
    Fabio Bagnoli
    Novartis Vaccines and Diagnostics, Siena, Italy
    OMICS 15:545-66. 2011
    ..Finally, we present a discussion to situate omics-guided rational vaccine design in the broader context of global public health and how it can benefit citizens in both developed and developing countries...
  57. ncbi request reprint The impact of genomics on vaccine design
    Maria Scarselli
    Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Trends Biotechnol 23:84-91. 2005
    ..In this review, we describe how genomic approaches can be used to identify novel vaccine candidates or create safer live-attenuated vaccines...
  58. pmc Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections
    Annalisa Nuccitelli
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 108:10278-83. 2011
    ..In addition, this work describes a template procedure that can be followed to develop vaccines against other bacterial pathogens...
  59. ncbi request reprint Ng-MIP, a surface-exposed lipoprotein of Neisseria gonorrhoeae, has a peptidyl-prolyl cis/trans isomerase (PPIase) activity and is involved in persistence in macrophages
    Rosanna Leuzzi
    IRIS, Chiron s r l, Via Fiorentina, 1, 53100 Siena, Italy
    Mol Microbiol 58:669-81. 2005
    ..We show that Ng-MIP promotes the intracellular survival of N. gonorrhoeae in macrophages, highlighting a possible role of this protein in promoting the persistence of gonococcal infection...
  60. ncbi request reprint The genome revolution in vaccine research
    Barbara Capecchi
    IRIS, Chiron s r l, Via Fiorentina 1, 53100 Siena, Italy
    Curr Issues Mol Biol 6:17-27. 2004
    ..The concept of "Reverse Vaccinology" can be easily applied to all the pathogens for which vaccines are not yet available and can be extended to parasites and viruses...
  61. pmc Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene
    Giuseppe Del Giudice
    Research Center, Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Clin Vaccine Immunol 13:1010-3. 2006
    ..In conclusion, antisqualene antibodies are not increased by immunization with vaccines with the MF59 adjuvant. These data extend the safety profile of the MF59 emulsion adjuvant...
  62. pmc N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines
    Karin Baraldo
    Research Center, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Infect Immun 72:4884-7. 2004
    ..N19-based conjugates are superior to CRM-based conjugates to induce protective immune responses to MenC conjugates...
  63. ncbi request reprint Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis
    Isabel Delany
    Biochemistry and Molecular Biology Unit, IRIS, Chiron s r l, Via Fiorentina 1, 53100 Siena, Italy
    Mol Microbiol 52:1081-90. 2004
    ..Deletion of the upstream operator in the norB promoter abolished activation of transcription in vivo in response to iron and in vitro in response to Fur. The role of such a dual mechanism of Fur regulation during infection is discussed...
  64. pmc NadA diversity and carriage in Neisseria meningitidis
    Maurizio Comanducci
    IRIS, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Infect Immun 72:4217-23. 2004
    ..The presence of NadA can therefore be used as a tool to study the dynamics of meningococcal infections and understand why this bacterium, which is mostly a commensal, can become a severe pathogen...
  65. pmc Effect of Neisseria meningitidis fur mutations on global control of gene transcription
    Isabel Delany
    Molecular Immunology Unit, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    J Bacteriol 188:2483-92. 2006
    ..We began to dissect the regulatory networks of Fur and the heat shock (stress) response in N. meningitidis, and the observed interlink between the two circuits is discussed...
  66. doi request reprint Seasonal influenza vaccine provides priming for A/H1N1 immunization
    Giuseppe Del Giudice
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Sci Transl Med 1:12re1. 2009
    ..The vaccine given without adjuvant significantly reduced viral load in the lungs but did not protect from infection. Only the vaccine with adjuvant completely prevented both pulmonary and nasal infection...
  67. pmc Identification of an iron-sulfur cluster that modulates the enzymatic activity in NarE, a Neisseria meningitidis ADP-ribosyltransferase
    Mariangela Del Vecchio
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    J Biol Chem 284:33040-7. 2009
    ..This is the first observation suggesting that a member of the ADP-ribosyltransferase family contains an Fe-S cluster implicated in catalysis. This observation may unravel novel functions exerted by this class of enzymes...
  68. doi request reprint One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies
    Elisa Faenzi
    Research Development, Novartis Vaccines and Diagnostics Srl, Siena, Italy
    Vaccine 30:4086-94. 2012
    ..These data shed light on the different components of the immune response to the 2009 H1N1 pandemic influenza vaccination and may have implications in the design of vaccination strategies against future influenza pandemics...
  69. doi request reprint Human heat shock protein (Hsp) 90 interferes with Neisseria meningitidis adhesin A (NadA)-mediated adhesion and invasion
    Paolo Montanari
    Research Center, Novartis Vaccines and Diagnostics, Siena, Italy
    Cell Microbiol 14:368-85. 2012
    ..Altogether our results show that variation of host Hsp90 expression or activity interferes with adhesive and invasive events driven by NadA...
  70. ncbi request reprint Long-term solutions for the problem of vaccine shortages
    Maria Lattanzi
    Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Expert Opin Biol Ther 4:989-92. 2004
    ..This article will provide examples of how public-private partnerships both in developed and developing countries have been established to handle specific problems concerning vaccination...
  71. pmc Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli
    Danilo Gomes Moriel
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 107:9072-7. 2010
    ..The gene encoding the most protective antigen was detected in most of the E. coli isolates, highly conserved in sequence and found to be exported by a type II secretion system which seems to be nonfunctional in nonpathogenic strains...
  72. pmc Dual control of Helicobacter pylori heat shock gene transcription by HspR and HrcA
    Gunther Spohn
    Biochemistry and Molecular Biology Unit, IRIS, 53100 Siena, Italy
    J Bacteriol 186:2956-65. 2004
    ..The implications of these findings for the elucidation of the networks regulating heat shock gene expression in H. pylori are discussed...
  73. ncbi request reprint Genome-based vaccine development: a short cut for the future
    Danilo Gomes Moriel
    Novartis Vaccines, Siena, Italy
    Hum Vaccin 4:184-8. 2008
    ..A lot of work must be done, but deciphering the information provided by genome sequences and using it to better understand the host-pathogen interactions has proved to be the key for protection...
  74. doi request reprint The use of genomics in microbial vaccine development
    Stefania Bambini
    Novartis Vaccines, Siena, Italy
    Drug Discov Today 14:252-60. 2009
    ..Overall, the conventional empiric approach to vaccine development is being replaced by vaccine design. The recent development of synthetic genomics may provide a further opportunity to design vaccines...
  75. pmc CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription
    Raffaele Ieva
    Biochemistry and Molecular Biology Unit, Chiron Vaccines, 53100 Siena, Italy
    J Bacteriol 187:3421-30. 2005
    ..The role of CrgA in the regulation of gene expression during the infectious cycle of N. meningitidis is discussed...
  76. ncbi request reprint Vaccines in the era of genomics: the pneumococcal challenge
    Michèle Anne Barocchi
    Novartis Vaccines, Via Fiorentina, 53100 Siena, Italy
    Vaccine 25:2963-73. 2007
    ..Ultimately, the identification of immunogenic surface antigens and assessment of their efficacy will be imperative in the development of a vaccine with the ability to protect against invasive disease independent of serotype...
  77. doi request reprint Microbiology in the post-genomic era
    Duccio Medini
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Nat Rev Microbiol 6:419-30. 2008
    ....
  78. ncbi request reprint The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials
    Alessandro Muzzi
    Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Drug Discov Today 12:429-39. 2007
    ....
  79. ncbi request reprint Reverse vaccinology and genomics
    Rino Rappuoli
    IRIS, Chiron Vaccines, 53100 Siena, Italy
    Science 302:602. 2003
    ..The genomic revolution has had a dramatic effect on our ability to find new vaccine targets and develop effective vaccines...
  80. pmc The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies
    Marzia Monica Giuliani
    IRIS, Chiron Vaccines, Via Fiorentina 1, 53100 Siena, Italy
    Infect Immun 73:1151-60. 2005
    ..Arginine in position 204 was identified as important for binding of the monoclonal antibody. The identification of the region containing bactericidal epitopes is an important step in the design of new vaccines against meningococci...
  81. ncbi request reprint An anti-repression Fur operator upstream of the promoter is required for iron-mediated transcriptional autoregulation in Helicobacter pylori
    Isabel Delany
    Biochemistry and Molecular Biology Unit, IRIS, Chiron S rl, Via Fiorentina 1, 53100 Siena, Italy
    Mol Microbiol 50:1329-38. 2003
    ..We propose that its role is ensuring that Fur expression is not repressed below a minimum threshold level. Our data supports a novel promoter architecture and mechanism of regulation by Fur...
  82. doi request reprint Generating memory with vaccination
    Flora Castellino
    Research Center, Novartis Vaccines, Siena, Italy
    Eur J Immunol 39:2100-5. 2009
    ..We will also discuss how extending clinical investigation to events occurring early after vaccination can help identify early predictive markers of protective memory and thus contribute to faster development of better and safer vaccines...
  83. ncbi request reprint Factor H-binding protein, a unique meningococcal vaccine antigen
    Mariagrazia Pizza
    Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 26:I46-8. 2008
    ..fHbp is important for survival in human blood, human sera, and in presence of antimicrobial peptides, independently of its expression level. All these properties make fHbp a unique vaccine antigen...
  84. ncbi request reprint Pili in gram-positive pathogens
    John L Telford
    Novartis Vaccines and Diagnostics Srl, Via Fiorentina 1, 53100 Siena, Italy
    Nat Rev Microbiol 4:509-19. 2006
    ....
  85. ncbi request reprint The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines
    Barbara C Baudner
    IRIS Research Center, Chiron SpA, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 21:3837-44. 2003
    ..These results demonstrate that the concomitant use of chitosan microparticles and the LTK63 mutant significantly enhances the immunogenicity and the protective efficacy of vaccines given intranasally...
  86. ncbi request reprint Isogenic mutants of the cag pathogenicity island of Helicobacter pylori in the mouse model of infection: effects on colonization efficiency
    Marta Marchetti
    Immunobiological Research Institute of Siena IRIS Chiron Spa, Via Fiorentina 1, 53100 Siena, Italy
    Microbiology 148:1447-56. 2002
    ..These results suggest that the structure of the H. pylori secretion apparatus itself is involved in this process...
  87. ncbi request reprint An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
    Giuseppe Del Giudice
    Chiron Vaccines, Research Center and Clinical Research, Via Fiorentina 1, 53100 Siena, Italy
    Vaccine 24:3063-5. 2006
    ..We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine...
  88. doi request reprint MF59 adjuvant: the best insurance against influenza strain diversity
    Derek T O'Hagan
    Novartis Vaccines and Diagnostics, Cambridge, MA, USA
    Expert Rev Vaccines 10:447-62. 2011
    ....
  89. doi request reprint Influenza vaccine immunology
    Philip R Dormitzer
    Novartis Vaccines and Diagnostics, Siena, Italy
    Immunol Rev 239:167-77. 2011
    ..The MF59 adjuvant broadens the distribution of B-cell epitopes recognized on HA and NA following immunization...
  90. doi request reprint Structure-based antigen design: a strategy for next generation vaccines
    Philip R Dormitzer
    Novartis Vaccines and Diagnostics, Inc, 350 Massachusetts Ave, Cambridge, MA 02139, USA
    Trends Biotechnol 26:659-67. 2008
    ..Understanding the structural basis for immunogenicity and immunodominance will allow us to improve vaccine efficacy and broaden the range of vaccine-preventable diseases...
  91. ncbi request reprint Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays
    Renata Grifantini
    Chiron SpA, Via Fiorentina 1, 53100 Siena, Italy
    Nat Biotechnol 20:914-21. 2002
    ....
  92. doi request reprint A novel epigenetic regulator associated with the hypervirulent Neisseria meningitidis clonal complex 41/44
    Kate L Seib
    Microbial Molecular Biology, Novartis Vaccines, Via Fiorentina, 1, 53100 Siena, Italy
    FASEB J 25:3622-33. 2011
    ..The modulation of gene expression via the ModD phase-variable regulon (phasevarion), and its significant association with the cc41/44, suggest a role in the fitness and/or pathogenesis of strains belonging to the cc41/44...
  93. ncbi request reprint Towards a vaccine against Escherichia coli-associated urinary tract infections
    Laura Serino
    Novartis Vaccines and Diagnostics, Research Centre, Via Fiorentina 1, 53100 Siena, Italy
    Future Microbiol 5:351-4. 2010
    ....
  94. pmc Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88
    Anja Seubert
    Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 108:11169-74. 2011
    ..Because MF59 did not activate any of the Toll-like receptors in vitro, we propose that MF59 requires MyD88 for a Toll-like receptor-independent signaling pathway...
  95. pmc Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro
    George F Santos
    Novartis Vaccines, 350 Mass Ave, Cambridge, MA 02139, USA
    Clin Vaccine Immunol 16:1693-5. 2009
    ..Serum bactericidal antibody titers against selected bacteria were within assay variability through a selection event frequency of 1 in 10(-5). No change in antigen expression was observed by Western blotting...
  96. ncbi request reprint Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications
    Michael Broker
    Novartis Vaccines and Diagnostics GmbH, Marburg, Germany
    Biologicals 39:195-204. 2011
    ..Additional clinical applications of CRM(197), as in chemotherapy, also exist...
  97. ncbi request reprint Development of vaccines against Helicobacter pylori
    Giuseppe Del Giudice
    Research Center, Novartis Vaccines and Diagnostics, 53100 Siena, Italy
    Expert Rev Vaccines 8:1037-49. 2009
    ..These data show that vaccination against this pathogen is feasible. More research is required to understand the immunological mechanisms underlying immune-mediate protection...
  98. ncbi request reprint Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages
    Michael Broker
    Novartis Vaccines and Diagnostics GmbH and Co KG, 35041 Marburg, Germany
    Vaccine 27:5574-80. 2009
    ....
  99. doi request reprint Alum adjuvanticity: unraveling a century old mystery
    Ennio De Gregorio
    Department of Immunology, Novartis Vaccines and Diagnostics, Siena, Italy
    Eur J Immunol 38:2068-71. 2008
    ..Surprisingly, these three studies reported conflicting results on the requirement of the Nlrp3 inflammasome complex for alum adjuvant effects in vivo. This commentary attempts to resolve some of these discrepancies...